<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653220</url>
  </required_header>
  <id_info>
    <org_study_id>2019/00861</org_study_id>
    <nct_id>NCT04653220</nct_id>
  </id_info>
  <brief_title>Metabolic Response Evaluation of Low-sugar Snack Bars</brief_title>
  <official_title>Metabolic Response Evaluation of Low-sugar Snack Bars</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Nutrition Research Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Nutrition Research Centre, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the post-prandial metabolic response and biomarker response, following the&#xD;
      consumption of newly developed low glycaemic index (GI) snack bars. The snack bars are&#xD;
      formulated with different combinations and ratios of ingredients and food structures. The low&#xD;
      sugar products maintaining glucose homeostasis and preventing metabolic problems may have&#xD;
      commercial potential as a novel functional ingredient in a variety of fields, including&#xD;
      nutrition, medicine, and agriculture.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study we will study and compare the postprandial metabolic response of 5 snack bar&#xD;
      variants, 1 control product and 2 glucose (25g) reference drinks. The study will have a total&#xD;
      of 8 test sessions in a non-blinded, crossover design. Online computer software will be used&#xD;
      for simple randomization of the sequence of the 8 treatments (http://www.randomizer.org/).The&#xD;
      5 snack bars variants will be similar in macronutrient composition but will differ in the&#xD;
      source of carbohydrate, fibre and protein (rice, bamboo, inulin, soy, promitor). They will be&#xD;
      compared to a visually similar control product (crokao) that is higher in sugar. The&#xD;
      reference drink will be anhydrous glucose (25g) dissolved in 250 ml of water.Study&#xD;
      population: 15-20 participants will be recruited from each of the following ethnicities:&#xD;
      Chinese, Indian and Caucasian. During the screening session, participants will receive an&#xD;
      informed consent form and given ample time to go through it and rectify any queries they have&#xD;
      with the researcher. The number of test sessions will be discussed between the researcher and&#xD;
      the participants, depending on the volunteer's schedule. If they decide to take part in the&#xD;
      study, they will be asked to sign the informed consent form. They will then be asked to&#xD;
      complete a screening questionnaire and subsequently baseline measurements including&#xD;
      anthropometric measurements, blood pressure, and fasting blood glucose will be collected from&#xD;
      each participant in order to determine their eligibility. The screening questionnaire will&#xD;
      include demographic, general health details, and physical activity level. This information&#xD;
      will be used to determine whether the participant is eligible for the study, as well as to&#xD;
      check for any possible confounders that may influence the study outcomes. Anthropometric&#xD;
      measurements: Body weight and body composition will be measured using bioelectrical impedance&#xD;
      analysis (Tanita scale). Height will be measured using a stadiometer in order to calculate&#xD;
      participants' BMI. Waist circumference will be measured at the minimum circumference between&#xD;
      the iliac crest and the rib cage and hip circumference will be measured at the maximum&#xD;
      protuberance of the buttocks. Blood pressure will be measured using an Omron blood pressure&#xD;
      monitor (Model HEM-907) at baseline. Participants will be seated for five minutes before&#xD;
      blood pressure is measured. Measurements will be taken in duplicate and the averaged results&#xD;
      will be recorded.&#xD;
&#xD;
      Study protocol: The day before a test day, participants will be encouraged to consume their&#xD;
      usual diet and avoid alcohol consumption and participating in vigorous exercise. On test&#xD;
      days, participants will arrive at the laboratory after an overnight fast of 10 h. Upon&#xD;
      arrival, participants will be asked to void, and have their weight and body fat assessed with&#xD;
      a Tanita scale. After that, participants will enter the clinical suit and rest for 15 min&#xD;
      before a blood catheter is inserted in the antecubital vein of the arm. After the blood&#xD;
      catheter is inserted, participants will rest for 15 min, before two baseline blood sample (6&#xD;
      mL) are taken 10 minutes apart (-10 min and 0 min). Immediately after the second sample,&#xD;
      participants will be served a test food that has to be consumed within 15 min. Subsequently&#xD;
      blood samples (6mL) are obtained at 15, 30, 45, 60, 90,120, 180 and 240min. Appetite&#xD;
      sensations (e.g. hunger, fullness, desire-to-eat etc.) will also be measured using&#xD;
      questionnaires at similar time points when blood samples are taken. Subjects will be asked to&#xD;
      rate their appetite sensations on a 100 mm visual analogue scale (VAS). After each session,&#xD;
      the blood catheter will be removed. The participants will leave the laboratory and they will&#xD;
      be asked to keep a food diary of what they eat for the remaining day. Participants will&#xD;
      return until all test foods are consumed. During the entire test session, the subject will&#xD;
      have to stay rested and in the laboratory. Television and a workspace will be provided to the&#xD;
      subject.Blood samples will be will analysed for METABOLIC RESPONSE (glucose, insulin,&#xD;
      Triglycerides, NEFA, GLP-1 and ghrelin). A 100 uL aliquot of blood during the first blood&#xD;
      sample collection (T = -10min) will be obtained from each participant on the first day of&#xD;
      treatment (thus only once) for baseline metabolomics profiling.A stool sample from each&#xD;
      participant will be obtained to perform the following on the microbiome: DNA extraction,&#xD;
      library prep, 16S and shotgun (whole genome) sequencing, and demultiplexing of genomic data.&#xD;
      The stool sample will be collected between the screening session and the last test session&#xD;
      (time of collection will not influence the sample analysis). The participant will be&#xD;
      encouraged to collect the stool sample during one of the sessions at the research centre to&#xD;
      eliminate transport of the sample.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized crossover study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participant is blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in postprandial blood glucose over 240 minutes period</measure>
    <time_frame>240 minutes</time_frame>
    <description>Venous Blood obtained through canula, analysed using Beckman Coulter analyser.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial plasma insulin over 240 minutes period</measure>
    <time_frame>240 minutes</time_frame>
    <description>Venous blood obtain through cannula, analysed using Beckman Coulter analyser.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial plasma triglycerides over 240 minutes period</measure>
    <time_frame>240 minutes</time_frame>
    <description>Venous blood obtain through cannula, analysed using Beckman Coulter analyser.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial plasma non esterified fatty acids over 240 minutes period</measure>
    <time_frame>240 minutes</time_frame>
    <description>Venous blood obtain through cannula, analysed using chemistry analyser.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial plasma active ghrelin over 240 minutes period</measure>
    <time_frame>240 minutes</time_frame>
    <description>Venous blood obtain through cannula, analysed using ELISA analyser.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial plasma active GLP-1 over 240 minutes period</measure>
    <time_frame>240 minutes</time_frame>
    <description>Venous blood obtain through cannula, analysed using ELISA analyser.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pre Diabetes</condition>
  <condition>Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Control 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Glucose 25g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Glucose 25g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Crokao</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Commercially available snack bar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low sugar variant 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low sugar snack bar with sticky rice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low sugar variant 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low sugar snack bar with promitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low sugar variant 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low sugar snack bar with inulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low sugar variant 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low sugar snack bar with yellow soy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low sugar variant 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low sugar snack bar with rice syrup</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control 1</intervention_name>
    <description>25g glucose dissolve in 250ml of water</description>
    <arm_group_label>Control 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control 2</intervention_name>
    <description>25g glucose dissolve in 250ml of water</description>
    <arm_group_label>Control 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Crokao</intervention_name>
    <description>Standard Crokao containing 25g of available carbohydrate</description>
    <arm_group_label>Standard Crokao</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low sugar variant 1</intervention_name>
    <description>Low sugar variant 1 containing 25g of available carbohydrate</description>
    <arm_group_label>Low sugar variant 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low sugar variant 2</intervention_name>
    <description>Low sugar variant 2 containing 25g of available carbohydrate</description>
    <arm_group_label>Low sugar variant 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low sugar variant 3</intervention_name>
    <description>Low sugar variant 3 containing 25g of available carbohydrate</description>
    <arm_group_label>Low sugar variant 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low sugar variant 4</intervention_name>
    <description>Low sugar variant 4 containing 25g of available carbohydrate</description>
    <arm_group_label>Low sugar variant 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low sugar variant 5</intervention_name>
    <description>Low sugar variant 5 containing 25g of available carbohydrate</description>
    <arm_group_label>Low sugar variant 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Age between 21-65 years&#xD;
&#xD;
          -  Chinese, Indian and Caucasian Ethnicity&#xD;
&#xD;
          -  Body mass index between 18.5 - 25.5 kg/m2&#xD;
&#xD;
          -  Fasting blood glucose &lt;7.0 mmol/L&#xD;
&#xD;
          -  Normal blood pressure (&lt;140/90 mmHg)&#xD;
&#xD;
          -  In general good health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Partake in sports at a high competitive and/or endurance levels&#xD;
&#xD;
          -  Intentionally restrict food intakeHave known glucose-6-phosphate dehydrogenase (G6PD)&#xD;
             deficiency&#xD;
&#xD;
          -  Have poor veins impeding venous access and have any history of severe vasovagal&#xD;
             syncope (blackouts or near faints) following blood draws&#xD;
&#xD;
          -  Have metabolic diseases (such as diabetes, hypertension, etc.)&#xD;
&#xD;
          -  have medical conditions and/or taking medications known to affect glycemia&#xD;
             (glucocorticoids, thyroid hormones, thiazide diuretics)&#xD;
&#xD;
          -  Have any major organ dysfunction (e.g. cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal) that may influence taste, olfaction, appetite, digestion,&#xD;
             metabolism, absorption or elimination of test foods, nutraceutical or drug,&#xD;
&#xD;
          -  Have any severe food allergy or food intolerance&#xD;
&#xD;
          -  Having active Tuberculosis (TB) or currently receiving treatment for TB&#xD;
&#xD;
          -  Have any known Chronic Infection or known to suffer from or have previously suffered&#xD;
             from or is a carrier of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human&#xD;
             Immunodeficiency Virus (HIV)&#xD;
&#xD;
          -  Are a member of the research team or their immediate family members. Immediate family&#xD;
             member is defined as a spouse, parent, child, or sibling, whether biological or&#xD;
             legally adopted&#xD;
&#xD;
          -  Concurrent participation in a study that might affect the outcomes of the current&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>All healthy male subjects</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeyakumar C Henry, PhD</last_name>
    <phone>6407 0793</phone>
    <email>jeya_henry@sifbi.a-star.edu.sg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan GJA Camps, PhD</last_name>
    <phone>6407 4357</phone>
    <email>Stefan_Camps@sifbi.a-star.edu.sg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Nutrition Research Centre</name>
      <address>
        <city>Singapore</city>
        <zip>117599</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeyakumar C Henry, PhD</last_name>
      <phone>6407 0793</phone>
      <email>jeya_henry@sifbi.a-star.edu.sg</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Gerardus JA Camps, PhD</last_name>
      <phone>6407 4357</phone>
      <email>Stefan_Camps@sifbi.a-star.edu.sg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 27, 2020</study_first_submitted>
  <study_first_submitted_qc>November 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Nutrition Research Centre, Singapore</investigator_affiliation>
    <investigator_full_name>JeyaKumar Henry</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

